Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

TJ Schroeder

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Procedures

Physiology

Chemicals & Drugs

Concepts & Ideas

Disorders

Acute Disease

Living Beings

Tissue Donors

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
87
First, Roy
30
Alexander, Wesley
21
Pesce, Amadeo
17
Munda, Rino
15
Peddi, Ram
13
Weiskittel, Pat
11
Balistreri, William
9
Ryckman, Frederick
9
Penn, I
9
Melvin, David
9
Moore, Linda
8
Gaber, Osama
7
Martin, Jill
7
Pouletty, P
6
Hariharan, S

Sign-in to see all Coauthors

Publications

TOP 3
Schnitzler M A; Woodward R S; Lowell J A; Amir L; Schroeder T J; Singer G G; Brennan D C
Economics of the antithymocyte globulins Thymoglobulin and Atgam in the treatment of acute renal transplant rejection.
Dean D E; Kamath S; Peddi V R; Schroeder T J; First M R; Cavallo T
A blinded retrospective analysis of renal allograft pathology using the Banff schema: implications for clinical management.
Regan J F; Campbell K; Van Smith L; Schroeder T J; Womble D; Kano J; Buelow R
Sensitization following Thymoglobulin and Atgam rejection therapy as determined with a rapid enzyme-linked immunosorbent assay. US Thymoglobulin Multi-Center Study Group.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of TJ Schroeder (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2000: Schnitzler M A; Woodward R S; Lowell J A; Amir L; Schroeder T J; Singer G G; Brennan D C
Economics of the antithymocyte globulins Thymoglobulin and Atgam in the treatment of acute renal transplant rejection.
PharmacoEconomics 2000;17(3):287-93.
1999: Dean D E; Kamath S; Peddi V R; Schroeder T J; First M R; Cavallo T
A blinded retrospective analysis of renal allograft pathology using the Banff schema: implications for clinical management.
Transplantation 1999;68(5):642-5.
1999: Regan J F; Campbell K; Van Smith L; Schroeder T J; Womble D; Kano J; Buelow R
Sensitization following Thymoglobulin and Atgam rejection therapy as determined with a rapid enzyme-linked immunosorbent assay. US Thymoglobulin Multi-Center Study Group.
Transplant immunology 1999;7(2):115-21.
1999: Shah M B; Martin J E; Schroeder T J; First M R
The evaluation of the safety and tolerability of two formulations of cyclosporine: neoral and sandimmune. A meta-analysis.
Transplantation 1999;67(11):1411-7.
1999: Gaber L W; Moore L W; Gaber A O; Tesi R J; Meyer J; Schroeder T J
Correlation of histology to clinical rejection reversal: a thymoglobulin multicenter trial report.
Kidney international 1999;55(6):2415-22.
1999: Schnitzler M A; Woodward R S; Lowell J A; Singer G G; Amir L; Horn H R; Kano J M; Schroeder T J; Brennan D C
Costs savings associated with thymoglobulin for treatment of acute renal transplant rejection in patient subsets.
Transplantation proceedings 1999;31(3B Suppl):7S-8S.
1999: Schroeder T J; Moore L W; Gaber L W; Gaber A O; First M R
The US multicenter double-blind, randomized, phase III trial of thymoglobulin versus atgam in the treatment of acute graft rejection episodes following renal transplantation: rationale for study design.
Transplantation proceedings 1999;31(3B Suppl):1S-6S.
1999: Martin J E; Daoud A J; Schroeder T J; First M R
The clinical and economic potential of cyclosporin drug interactions.
PharmacoEconomics 1999;15(4):317-37.
1999: Peddi V R; Schroeder T J; Weiskittel P; First M R
Graft outcome in patients with biopsy-proven chronic renal allograft rejection.
Transplantation proceedings 1999;31(1-2):1308-9.
1999: Fisher R A; Pan S H; Rossi S J; Schroeder T J; Irish W D; Canafax D M; Lopez R R
Pharmacokinetic comparison of two cyclosporine A formulations, SangCya (Sang-35) and Neoral, in stable adult liver transplant recipients.
Transplantation proceedings 1999;31(1-2):394-5.
1999: Gaston R; Alloway R R; Gaber A O; Rossi S J; Schroeder T J; Irish W D; Canafax D M; First M R
Pharmacokinetic and safety evaluation of SangCya vs Neoral or Sandimmune in stable renal transplant recipients.
Transplantation proceedings 1999;31(1-2):326-7.
1999: First M R; Weiskittel P; Burton M L; Shah M B; Dreyer D; Fleck P; Bey C; Peddi V R; Canafax D M; Schroeder T J
Nine-month follow-up of SangCya (Sang-35) in kidney transplant patients after conversion from Sandimmune.
Transplantation proceedings 1999;31(1-2):324-5.
1999: Khosla U M; Martin J E; Baker G M; Schroeder T J; First M R
One-year, single-center cost analysis of mycophenolate mofetil versus azathioprine following cadaveric renal transplantation.
Transplantation proceedings 1999;31(1-2):274-5.
1999: Shah M B; Martin J E; Schroeder T J; First M R
Validity of open labeled versus blinded trials: a meta-analysis comparing Neoral and Sandimmune.
Transplantation proceedings 1999;31(1-2):217-9.
1998: Baker G M; Martin J E; Jang R; Schroeder T J; Armitstead J A; Myre S; First M R
Pharmacoeconomic analysis of mycophenolate mofetil versus azathioprine in primary cadaveric renal transplantation.
Transplantation proceedings 1998;30(8):4082-4.
1998: Daoud A J; Schroeder T J; Shah M; Hariharan S; Peddi V R; Weiskittel P; First M R
A comparison of the safety and efficacy of mycophenolate mofetil, prednisone and cyclosporine and mycophenolate mofetil, and prednisone and tacrolimus.
Transplantation proceedings 1998;30(8):4079-81.
1998: Fleck P R; Schroeder T J; Dauod A J; Peddi V R; First M R
Tacrolimus use in kidney-pancreas recipients is associated with less acute renal dysfunction than cyclosporine.
Transplantation proceedings 1998;30(8):4070-2.
1998: Shah M B; Martin J E; Schroeder T J; First M R
A meta-analysis to assess the safety and tolerability of two formulations of cyclosporine: Sandimmune and Neoral.
Transplantation proceedings 1998;30(8):4048-53.
1998: First M R; Weiskittel P; Shah M; Peddi V R; Canafax D; Schroeder T J
Conversion of stable renal transplant recipients from Sandimmune to Sang-35, a Neoral-equivalent cyclosporine formulation, using a dose-adjusted method.
Transplantation proceedings 1998;30(8):3955-7.
1998: First M R; Alloway R; Schroeder T J
Development of Sang-35: a cyclosporine formulation bioequivalent to Neoral.
Clinical transplantation 1998;12(6):518-24.
1998: Schroeder T J; Cho M J; Pollack G M; Floc'h R; Moran H B; Levy R; Moore L W; Pouletty P
Comparison of two cyclosporine formulations in healthy volunteers: bioequivalence of the new Sang-35 formulation and Neoral.
Journal of clinical pharmacology 1998;38(9):807-14.
1998: Thielke J; Martin J; Weber F L; Schroeder T J; Goretsky S; Hanto D W
Pharmacokinetics of tacrolimus and cyclosporine in short-bowel syndrome.
Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 1998;4(5):432-4.
1998: First M R; Weiskittel P; Burton M; Shah M; Dreyer D; Fleck P; Bey C; Peddi R; Canafax D; Schroeder T J
Conversion of stable renal transplant recipients from Sandimmune to Sang-35, a novel cyclosporine formulation, using a dose-normalized equivalence method.
Transplantation proceedings 1998;30(5):1701-5.
1998: Shah M B; Martin J E; Schroeder T J; First M R
Evaluation of the safety and tolerability of Neoral and Sandimmune: a meta-analysis.
Transplantation proceedings 1998;30(5):1697-700.
1998: Gaber A O; First M R; Tesi R J; Gaston R S; Mendez R; Mulloy L L; Light J A; Gaber L W; Squiers E; Taylor R J; Neylan J F; Steiner R W; Knechtle S; Norman D J; Shihab F; Basadonna G; Brennan D C; Hodge E E; Kahan B D; Kahan L; Steinberg S; Woodle E S; Chan L; Ham J M; Schroeder T J
Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation.
Transplantation 1998;66(1):29-37.
1998: Martin J E; Fleck P; Schroeder T J; Whiting J F; Hanto D W
The cost of rejection in liver allograft recipients.
Transplantation proceedings 1998;30(4):1500-1.
1998: Kamath S; Dean D; Peddi V R; Schroeder T J; Alexander J W; Cavallo T; First M R
Primary therapy with OKT3 for biopsy-proven acute renal allograft rejection.
Transplantation proceedings 1998;30(4):1178-80.
1998: Bhat G; Schroeder T J; Balakrishnan K
Can anti-HLA antibody analyses postcardiac transplantation predict acute allograft rejection and survival?
Transplantation proceedings 1998;30(4):1154-7.
1998: Gaber A O; Moore L W; Schroeder T J
Observations on recovery of renal function following treatment for acute rejection.
American journal of kidney diseases : the official journal of the National Kidney Foundation 1998;31(6 Suppl 1):S47-59.
1998: Guttmann R D; Soulillou J P; Moore L W; First M R; Gaber A O; Pouletty P; Schroeder T J
Proposed consensus for definitions and endpoints for clinical trials of acute kidney transplant rejection.
American journal of kidney diseases : the official journal of the National Kidney Foundation 1998;31(6 Suppl 1):S40-6.
1998: Schroeder T J; Moore L W
Efficacy Endpoints Conference on Acute Rejection in Kidney Transplantation: summary report of the database.
American journal of kidney diseases : the official journal of the National Kidney Foundation 1998;31(6 Suppl 1):S31-9.
1998: Alexander J W; Levy A; Custer D; Valente J F; Babcock G; Ogle C K; Schroeder T J
Arginine, fish oil, and donor-specific transfusions independently improve cardiac allograft survival in rats given subtherapeutic doses of cyclosporin.
JPEN. Journal of parenteral and enteral nutrition 1998;22(3):152-5.
1998: Peddi V R; Kamath S; Schroeder T J; Munda R; First M R
Efficacy of OKT3 as primary therapy for histologically confirmed acute renal allograft rejection in simultaneous kidney and pancreas transplant recipients.
Transplantation proceedings 1998;30(2):285-7.
1998: Gaber L W; Moore L W; Gaber A O; First M R; Guttmann R D; Pouletty P; Schroeder T J; Soulillou J P
Utility of standardized histological classification in the management of acute rejection. 1995 Efficacy Endpoints Conference.
Transplantation 1998;65(3):376-80.
1997: Bhat G; Schroeder T J
Clinical role of immunologic monitoring during OKT3 treatment.
Transplantation proceedings 1997;29(8A):21S-26S.
1997: Kamath S; Dean D; Peddi V R; Schroeder T J; Alexander J W; Cavallo T; First M R
Efficacy of OKT3 as primary therapy for histologically confirmed acute renal allograft rejection.
Transplantation 1997;64(10):1428-32.
1997: Daoud A J; Schroeder T J; Kano J; Horn H R; Moran H B; First M R
The US compassionate experience with thymoglobulin for the treatment of resistant acute rejection.
Transplantation proceedings 1997;29(7A):18S-20S.
1997: Daoud A J; Bhat G; Schroeder T J
Are surveillance endomyocardial biopsies necessary during OKT3 induction therapy?
Transplantation 1997;64(2):368-70.
1997: Valente J F; Hariharan S; Peddi V R; Schroeder T J; Ogle C K; Alexander J W; First M R
Causes of renal allograft loss in black vs. white transplant recipients in the cyclosporine era.
Clinical transplantation 1997;11(3):231-6.
1997: Regan J; Campbell K; van Smith L; Pouletty P; Schroeder T J; Guttmann R D; Buelow R
Characterization of anti-thymoglobulin, anti-Atgam and anti-OKT3 IgG antibodies in human serum with an 11-min ELISA.
Transplant immunology 1997;5(1):49-56.
1997: Hariharan S; Peddi V R; Munda R; Demmy A M; Schroeder T J; Alexander J W; First M R
Long-term renal and pancreas function with tacrolimus rescue therapy following kidney/pancreas transplantation.
Transplantation proceedings 1997;29(1-2):652-3.
1997: el-Ghoroury M; Hariharan S; Peddi V R; Munda R; Schroeder T J; Demmy A M; Alexander J W; First M R
Efficacy and safety of tacrolimus versus cyclosporine in kidney and pancreas transplant recipients.
Transplantation proceedings 1997;29(1-2):649-51.
1997: Schroeder T J; Levy R; Pouletty P; First M R
A generic cyclosporine development program.
Transplantation proceedings 1997;29(1-2):1235-8.
1997: Gaber L W; Moore L W; Gaber A O; First M R; Guttmann R D; Pouletty P; Schroeder T J; Soulillou J P
A multicenter report on the utilization of Banff grading in acute renal rejection. The 1995 Efficacy Endpoints Conference.
Transplantation proceedings 1997;29(1-2):184-5.
1997: Peddi V R; Dean D E; Hariharan S; Cavallo T; Schroeder T J; First M R
Proteinuria following renal transplantation: correlation with histopathology and outcome.
Transplantation proceedings 1997;29(1-2):101-3.
1997: Ram Peddi V; Hariharan S; Schroeder T J; First M R
Impact of ganciclovir prophylaxis on cytomegalovirus infection in recipients of cadaveric renal allografts.
Nephron 1997;76(1):49-55.
1996: Schroeder T J; Shah M; Hariharan S; First M R
Increased resources are required in patients with low cyclosporine bioavailability.
Transplantation proceedings 1996;28(4):2151-5.
1996: Gaber L W; Schroeder T J; Moore L W; Shakouh-Amiri M H; Gaber A O
The correlation of Banff scoring with reversibility of first and recurrent rejection episodes.
Transplantation 1996;61(12):1711-5.
1996: Hariharan S; Alexander J W; Schroeder T J; First M R
Outcome of cadaveric renal transplantation by induction treatment in the cyclosporine era.
Clinical transplantation 1996;10(2):186-90.
1996: Hariharan S; Munda R; Cavallo T; Demmy A M; Schroeder T J; Alexander J W; First M R
Rescue therapy with tacrolimus after combined kidney/pancreas and isolated pancreas transplantation in patients with severe cyclosporine nephrotoxicity.
Transplantation 1996;61(8):1161-5.
1996: First M R; Schroeder T J; Monaco A P; Simpson M A; Curtis J J; Armenti V T
Cyclosporine bioavailability: dosing implications and impact on clinical outcomes in select transplantation subpopulations.
Clinical transplantation 1996;10(1 Pt 1):55-9.
1996: Peddi V R; Hariharan S; Schroeder T J; First M R
Role of granulocyte colony stimulating factor (G-CSF) in reversing neutropenia in renal allograft recipients.
Clinical transplantation 1996;10(1 Pt 1):20-3.
1995: el-Ghoroury M; Hariharan S; Munda R; Demmy A M; Schroeder T J; Alexander J W; First M R
Comparison between methylprednisolone and OKT3 treatment for the first acute rejection episode in combined kidney and pancreas transplant recipients.
Transplantation proceedings 1995;27(6):3133-4.
1995: Peddi V R; Hariharan S; Munda R; Schroeder T J; First M R
Impact of ganciclovir prophylaxis on cytomegalovirus infection in cadaveric kidney vs combined kidney and pancreas transplantation.
Transplantation proceedings 1995;27(6):3076-7.
1995: Hariharan S; Munda R; Demmy A M; Schroeder T J; Alexander J W; First M R
Conversion from cyclosporine to tacrolimus after pancreas transplantation.
Transplantation proceedings 1995;27(6):2981-2.
1995: Schroeder T J; Hariharan S; First M R
Variations in bioavailability of cyclosporine and relationship to clinical outcome in renal transplant subpopulations.
Transplantation proceedings 1995;27(1):837-9.
1994: Ryckman F C; Schroeder T J; Pedersen S H; Dittrich V S; Balistreri W F
Induction therapy with OKT3 in pediatric liver-transplant recipients.
Transplantation science 1994;4 Suppl 1():S20-5.
1994: Schroeder T J; Hariharan S; First M R
Relationship between cyclosporine bioavailability and clinical outcome in renal transplant recipients.
Transplantation proceedings 1994;26(5):2787-90.
1994: Rossi S J; Schroeder T J; Muth K L; Hanto D W; Balistreri W F; Ryckman F C
Soluble interleukin-2 receptor monitoring during bacterial and viral infections in liver transplant recipients: a comparative evaluation.
Clinical transplantation 1994;8(5):479-84.
1994: Madden R L; Schroeder T J; Alexander J W; First M R
Single dose OKT3: adverse effects, pharmacokinetics, and anti-OKT3 antibody response.
Transplantation science 1994;4(1):111-4.
1994: Schroeder T J; Michael A T; First M R; Hariharan S; Bhat G; Hanto D W; Ryckman F C; Balistreri W F
Variations in serum OKT3 concentration based upon age, sex, transplanted organ, treatment regimen, and anti-OKT3 antibody status.
Therapeutic drug monitoring 1994;16(4):361-7.
1994: Rush D N; Henry S F; Jeffery J R; Schroeder T J; Gough J
Histological findings in early routine biopsies of stable renal allograft recipients.
Transplantation 1994;57(2):208-11.
1994: Schroeder T J; First M R
Monoclonal antibodies in organ transplantation.
American journal of kidney diseases : the official journal of the National Kidney Foundation 1994;23(1):138-47.
1993: Hariharan S; Schroeder T J; Weiskittel P; Alexander J W; First M R
Prednisone withdrawal in HLA identical and one haplotype-matched live-related donor and cadaver renal transplant recipients.
Kidney international. Supplement 1993;43():S30-5.
1993: Rossi S J; Schroeder T J; Hariharan S; First M R
Prevention and management of the adverse effects associated with immunosuppressive therapy.
Drug safety : an international journal of medical toxicology and drug experience 1993;9(2):104-31.
1993: Hariharan S; Schroeder T J; First M R
Effect of race on renal transplant outcome.
Clinical transplantation 1993;7(3):235-9.
1993: Schroeder T J; Sridhar N; Pesce A J; Alexander J W; First M R
Clinical correlations of cyclosporine-specific and -nonspecific assays in stable renal transplants, acute rejection, and cyclosporine nephrotoxicity.
Therapeutic drug monitoring 1993;15(3):190-4.
1993: First M R; Schroeder T J; Michael A; Hariharan S; Weiskittel P; Alexander J W
Cyclosporine-ketoconazole interaction. Long-term follow-up and preliminary results of a randomized trial.
Transplantation 1993;55(5):1000-4.
1993: Muth K L; Schroeder T J; Ryckman F C; Martin L A; Traylor D; Pedersen S H; Dittrich V S; Balistreri W F
Soluble interleukin-2 receptor levels in pediatric liver transplant recipients.
Transplantation proceedings 1993;25(2):1783-4.
1993: Schroeder T J; Hariharan S; First M R
Antibody response to OKT3 and methods for monitoring.
Transplantation proceedings 1993;25(2 Suppl 1):77-80.
1993: First M R; Schroeder T J; Hariharan S; Weiskittel P
Reduction of the initial febrile response to OKT3 with indomethacin.
Transplantation proceedings 1993;25(2 Suppl 1):52-4.
1993: First M R; Schroeder T J; Hariharan S
OKT3-induced cytokine-release syndrome: renal effects (cytokine nephropathy).
Transplantation proceedings 1993;25(2 Suppl 1):25-6.
1993: First M R; Schroeder T J; Michael A; Hariharan S; Weiskittel P; Alexander J W
Safety and efficacy of long-term cyclosporine-ketoconazole administration and preliminary results of a randomized trial.
Transplantation proceedings 1993;25(1 Pt 1):591-4.
1993: Alexander J W; Davies C B; First M R; Cofer B R; Munda R; Madden R L; Hariharan S; Schroeder T J
Single pretransplant donor-specific transfusion in cadaver and living related donor renal transplantation.
Transplantation proceedings 1993;25(1 Pt 1):485-7.
1993: Schroeder T J; First M R; Pouletty C; Hariharan S; Pouletty P
Rapid detection of anti-OKT3 antibodies with the Transtat assay.
Transplantation 1993;55(2):297-9.
1992: Rossi S J; Schroeder T J; Vine W H; A-Kader H H; Gremse D A; Ryckman F C; Pedersen S H; Pesce A J; Balistreri W F
Monoethylglycinexylide formation in assessing pediatric donor liver function.
Therapeutic drug monitoring 1992;14(6):452-6.
1992: Davies C B; Alexander J W; Cofer B R; First M R; Schroeder T J
Efficacy of a single pretransplant donor-specific transfusion and cyclosporin A administered 24 to 48 hours before one-haplotype-mismatched living related donor kidney transplant.
Annals of surgery 1992;215(6):618-25; discussion 626.
1992: Balistreri W F; A-Kader H H; Setchell K D; Gremse D; Ryckman F C; Schroeder T J
New methods for assessing liver function in infants and children.
Annals of clinical and laboratory science 1992;22(3):162-74.
1992: First M R; Schroeder T J; Hariharan S; Alexander J W; Weiskittel P
The effect of indomethacin on the febrile response following OKT3 therapy.
Transplantation 1992;53(1):91-4.
1992: Schroeder T J; Helling T; McKenna R M; Rush D; Jeffrey J R; Brewer B; Martin L A; Traylor D; Fisher R A; First M R
A multicenter study to evaluate a novel assay for quantitation of soluble interleukin 2 receptor in renal transplant recipients.
Transplantation 1992;53(1):34-40.
1991: First M R; Schroeder T J
Solid-organ transplantation in the pediatric population.
Clinical transplantation 1991;5(2 part 2):132-6.
1991: McKenna R M; Schroeder T J
Immunological monitoring in cyclosporine-treated patients.
Clinical biochemistry 1991;24(1):75-80.
1991: First M R; Schroeder T J; Alexander J W; Stephens G W; Weiskittel P; Myre S A; Pesce A J
Cyclosporine dose reduction by ketoconazole administration in renal transplant recipients.
Transplantation 1991;51(2):365-70.
1991: Fisher R A; Tchervenkov J I; Schroeder T J; Alexander J W; Munda R; Penn I; Carey M; First M R
Efficacy of induction therapy in cadaveric renal transplantation comparing rabbit antithymocyte serum and Minnesota antilymphoblast globulin.
Transplantation proceedings 1991;23(1 Pt 2):1253-5.
1991: Schroeder T J; Weiss M A; Smith R D; Stephens G W; First M R
The efficacy of OKT3 in vascular rejection.
Transplantation 1991;51(2):312-5.
1991: Schroeder T J; Weiss M A; Smith R D; Stephens G W; Carey M; First M R
The use of OKT3 in the treatment of acute vascular rejection.
Transplantation proceedings 1991;23(1 Pt 2):1043-5.
1991: Druckenbrod R W; Mendenhall C L; Myre S A; Stanberry E A; Schroeder T J
Effects of controlled liver injury and ethanol pretreatment on monoethylglycine xylidide formation in the rat.
Pharmacology 1991;42(3):169-76.
1991: Schroeder T J; Pesce A J; Ryckman F C; Tressler T P; Brunson M E; Pedersen S H; Tchervenkov J I; Penn I; Alexander J W; Balistreri W F
Selection criteria for liver transplant donors.
Journal of clinical laboratory analysis 1991;5(4):275-7.
1990: Gremse D A; A-Kader H H; Schroeder T J; Balistreri W F
Assessment of lidocaine metabolite formation as a quantitative liver function test in children.
Hepatology (Baltimore, Md.) 1990;12(3 Pt 1):565-9.
1990: Sridhar N; Schroeder T J; Pesce A J; First M R
Clinical correlations of cyclosporine HPLC and FPIA levels in renal transplant recipients.
Transplantation proceedings 1990;22(3):1257-9.
1990: Pesce A J; Schroeder T J; First M R
An evaluation of cyclosporine monitoring by nonselective fluorescence polarization immunoassay.
Transplantation proceedings 1990;22(3):1171-4.
1990: Schroeder T J; First M R; Mansour M E; Hurtubise P E; Hariharan S; Ryckman F C; Munda R; Melvin D B; Penn I; Ballistreri W F
Antimurine antibody formation following OKT3 therapy.
Transplantation 1990;49(1):48-51.
1990: Schroeder T J; Munda R; Pedersen S H; Hurtubise P E; Alexander J W; First M R
Failure of orthoclone OKT3 retreatment in a pancreas transplant recipient with antimurine antibodies.
Journal of clinical laboratory analysis 1990;4(2):99-101.
1989: First M R; Schroeder T J; Carey M A; Chavinson D S
Effect of race on transplant outcome and response to OKT3 monoclonal antibody therapy.
Transplantation proceedings 1989;21(6):3949-52.
1989: First M R; Schroeder T J; Weiskittel P; Myre S A; Alexander J W; Pesce A J
Concomitant administration of cyclosporin and ketoconazole in renal transplant recipients.
Lancet 1989;2(8673):1198-201.
1989: Schroeder T J; First M R; Mansour M E; Alexander J W; Penn I
Prophylactic use of OKT3 in immunologic high-risk cadaver renal transplant recipients.
American journal of kidney diseases : the official journal of the National Kidney Foundation 1989;14(5 Suppl 2):14-8.
1989: Wandstrat T L; Schroeder T J; Myre S A
Cyclosporine pharmacokinetics in pediatric transplant recipients.
Therapeutic drug monitoring 1989;11(5):493-6.
1989: Schroeder T J; First M R; Hurtubise P E; Marmer D J; Martin D M; Mansour M E; Melvin D B
Immunologic monitoring with Orthoclone OKT3 therapy.
The Journal of heart transplantation 1989;8(5):371-80.
1989: Schroeder T J; Gremse D A; Mansour M E; Theuerling A W; Brunson M E; Ryckman F C; Suchy F J; Penn I; Alexander J W; Pesce A J
Lidocaine metabolism as an index of liver function in hepatic transplant donors and recipients.
Transplantation proceedings 1989;21(1 Pt 2):2299-301.
1989: First M R; Schroeder T J; Hurtubise P E; Mansour M E; Penn I; Munda R; Balistreri W F; Alexander J W; Melvin D B; Fidler J P
Immune monitoring during retreatment with OKT3.
Transplantation proceedings 1989;21(1 Pt 2):1753-4.
1989: Hariharan S; First M R; Munda R; Penn I; Schroeder T J; Fidler J; Weiskittel P; Alexander J W
Prednisone withdrawal in HLA-identical living related donor transplant recipients.
Transplantation proceedings 1989;21(1 Pt 2):1617-9.
1989: First M R; Smith R D; Weiss M A; Schroeder T J; Kant K S; Munda R; Stephens G W; Penn I; Alexander J W
Cyclosporine-associated glomerular and arteriolar thrombosis following renal transplantation.
Transplantation proceedings 1989;21(1 Pt 2):1567-70.
1989: Myre S A; Schroeder T J; Melvin D B; Pesce A J; Collins J A; Stephens G W; First M R
Comparison of the safety and efficacy of oral vs constant-rate intravenous infusion cyclosporine immediately following orthotopic heart transplantation.
Transplantation proceedings 1989;21(1 Pt 3):2484-6.
1989: Schroeder T J; Brunson M E; Pesce A J; Hindenlang L L; Mauser P A; Ruckrigl D I; Weibel M L; Wadih G; First M R
A comparison of the clinical utility of the radioimmunoassay, high-performance liquid chromatography, and TDx cyclosporine assays in outpatient renal transplant recipients.
Transplantation 1989;47(2):262-6.
1989: Schroeder T J; Myre S A; Melvin D B; Van der Bel-Kahn J; Stephens G W; Collins J A; Wolf R K; Brown L L; Pesce A J; First M R
Efficacy and safety of constant-rate intravenous cyclosporine infusion immediately after heart transplantation.
The Journal of heart transplantation 1989;8(1):5-10.
1989: Tchervenkov J I; Epstein M D; Alexander J W; Schroeder T J
The effect of donor-specific blood transfusion, cyclosporine, and dietary prostaglandin precursors on rat cardiac allograft survival. II. Effectiveness of a 24-hour induction period with DST and CsA in inducing long-term graft survival.
Transplantation 1989;47(1):177-81.
1989: First M R; Schroeder T J; Hurtubise P E; Mansour M E; Penn I; Munda R; Balistreri W F; Alexander J W; Melvin D B; Fidler J P
Successful retreatment of allograft rejection with OKT3.
Transplantation 1989;47(1):88-91.
1989: Schroeder T J; Pesce A J; Hindenlang L L; Mauser P A; Ruckrigl D L; Weibel M L; Wadih G; First M R
An evaluation of the cyclosporine and metabolites whole blood TDx assay.
Therapeutic drug monitoring 1989;11(4):480-2.
1988: Clardy C W; Schroeder T J; Myre S A; Wadhwa N K; Pesce A J; First M R; McEnery P T; Balistreri W F; Harris R E; Melvin D B
Clinical variability of cyclosporine pharmacokinetics in adult and pediatric patients after renal, cardiac, hepatic, and bone-marrow transplants.
Clinical chemistry 1988;34(10):2012-5.
1988: Myre S A; Schroeder T J; Melvin D B; Clardy C W; Pesce A J; Wadhwa N K; Collins J A; Wolf R K; Brown L L; Stephens G W
Use of cyclosporine by constant-rate intravenous infusion immediately after heart transplantation.
Transplantation proceedings 1988;20(3 Suppl 3):316-22.
1988: Munda R; Schroeder T J; Pedersen S A; Clardy C W; Wadhwa N K; Myre S A; Stephens G W; Pesce A J; Alexander J W; First M R
Cyclosporine pharmacokinetics in pancreas transplant recipients.
Transplantation proceedings 1988;20(2 Suppl 2):487-90.
1988: Schroeder T J; Pesce A J; Hassan F M; Wermeling J R; Warner A; Schlueter K T; First M R
Comparison of Abbott TDx fluorescence polarization immunoassay, Sandoz radioimmunoassay, and high-performance liquid chromatography methods for the assay of serum cyclosporine.
Transplantation proceedings 1988;20(2 Suppl 2):345-7.
1987: Wadhwa N K; Schroeder T J; Pesce A J; Myre S A; Clardy C W; First M R
Cyclosporine drug interactions: a review.
Therapeutic drug monitoring 1987;9(4):399-406.
1987: Schroeder T J; Melvin D B; Clardy C W; Wadhwa N K; Myre S A; Reising J M; Wolf R K; Collins J A; Pesce A J; First M R
Use of cyclosporine and ketoconazole without nephrotoxicity in two heart transplant recipients.
The Journal of heart transplantation 1987;6(2):84-9.
1987: Wadhwa N K; Schroeder T J; O'Flaherty E; Pesce A J; Myre S A; First M R
The effect of oral metoclopramide on the absorption of cyclosporine.
Transplantation proceedings 1987;19(1 Pt 2):1730-3.
1987: Wadhwa N K; Schroeder T J; O'Flaherty E; Pesce A J; Myre S A; First M R
The effect of oral metoclopramide on the absorption of cyclosporine.
Transplantation 1987;43(2):211-3.
1987: Wadhwa N K; Schroeder T J; O'Flaherty E; Pesce A J; Myre S A; Munda R; First M R
Interaction between erythromycin and cyclosporine in a kidney and pancreas allograft recipient.
Therapeutic drug monitoring 1987;9(1):123-5.

Sign-in to see more